United Therapeutics Co. (NASDAQ:UTHR) Holdings Increased by National Pension Service

National Pension Service lifted its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 38.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,742 shares of the biotechnology company's stock after buying an additional 31,442 shares during the quarter. National Pension Service owned approximately 0.26% of United Therapeutics worth $40,759,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Robeco Institutional Asset Management B.V. increased its stake in shares of United Therapeutics by 3.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 196,019 shares of the biotechnology company's stock valued at $70,243,000 after acquiring an additional 6,839 shares during the last quarter. Emerald Advisers LLC purchased a new position in United Therapeutics during the third quarter worth approximately $692,000. Emerald Mutual Fund Advisers Trust acquired a new position in shares of United Therapeutics in the 3rd quarter valued at $111,000. Farther Finance Advisors LLC grew its stake in shares of United Therapeutics by 673.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 356 shares of the biotechnology company's stock valued at $128,000 after buying an additional 310 shares during the period. Finally, AustralianSuper Pty Ltd increased its holdings in shares of United Therapeutics by 12.0% during the 3rd quarter. AustralianSuper Pty Ltd now owns 28,029 shares of the biotechnology company's stock worth $10,044,000 after buying an additional 2,998 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 14,700 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total transaction of $5,504,562.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at approximately $964,983.42. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Christopher Causey sold 510 shares of the company's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael Benkowitz sold 14,700 shares of the firm's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares in the company, valued at $964,983.42. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,422 shares of company stock worth $29,229,828. Corporate insiders own 11.90% of the company's stock.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research analyst reports. LADENBURG THALM/SH SH lifted their target price on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a report on Thursday, October 31st. Morgan Stanley cut United Therapeutics from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. Bank of America decreased their price objective on shares of United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a research note on Thursday, August 1st. StockNews.com raised shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. Finally, Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Trading Up 1.3 %

UTHR stock traded up $5.08 during midday trading on Thursday, hitting $402.57. 370,193 shares of the company's stock were exchanged, compared to its average volume of 464,712. The stock has a market capitalization of $17.97 billion, a price-to-earnings ratio of 17.46, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56. The firm has a 50 day moving average price of $357.42 and a 200-day moving average price of $320.37. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $405.98.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm's quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.38 earnings per share. On average, sell-side analysts forecast that United Therapeutics Co. will post 25.57 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.